The Zhitong Finance App learned that on Thursday, Merck (MRK.US) went high. As of press release, the increase was more than 5%, with a market value of 365.8 billion US dollars. According to the news, MSD announced its results for the third quarter of 2026. The company's anti-cancer drug Keytruda (Keytruda) and the pulmonary hypertension drug WINREVAIR are driving revenue growth. Q3's total revenue was US$18.085 billion, up 5% year on year (excluding exchange rate impact of 4%), higher than LSEG's average analysts' average forecast of US$17.31 billion; adjusted earnings per share of US$2.49, far exceeding expectations of US$2.08; net profit of US$5,065 billion and earnings per share of US$2.04 in accordance with generally accepted accounting principles, down 12% year over year, respectively. The company raised its full-year guidance on the same day: the low end of the 2026 revenue range was raised from US$66.3 billion to US$66.8 billion, and the adjusted earnings per share guide for the full year rose from US$2.66 to US$2.76 to US$2.77 to US$2.82.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.